PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in ear ...

NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming ...

Overall, the top 16 largest pharmaceutical companies spent $159 billion on research and development in 2025, compared to $165 ...

When a person with cancer finds out they carry an inherited genetic variant that puts them at higher risk of cancer, the results can help inform their treatment or steps to prevent additional cancer.

By Tom Hudson This story was originally produced by WLRN, South Florida’s only public radio station at 91.3 FM, as part of a ...